vs
Side-by-side financial comparison of Sila Realty Trust, Inc. (SILA) and SOLENO THERAPEUTICS INC (SLNO). Click either name above to swap in a different company.
SOLENO THERAPEUTICS INC is the larger business by last-quarter revenue ($66.0M vs $50.1M, roughly 1.3× Sila Realty Trust, Inc.). SOLENO THERAPEUTICS INC runs the higher net margin — 39.4% vs 10.0%, a 29.4% gap on every dollar of revenue.
Sila Realty Trust, Inc. is a U.S.-based real estate investment trust that owns, operates, and acquires high-quality income-generating commercial properties. Its core portfolio covers industrial logistics facilities, office assets and mixed-use properties, serving tenants across logistics, corporate and retail segments to deliver stable long-term returns.
SOLENO THERAPEUTICS INC is a clinical-stage biopharmaceutical company specializing in developing novel therapies for rare endocrine, metabolic, and neurodevelopmental disorders. Its lead product candidate targets Prader-Willi syndrome, a rare genetic condition, with key patient markets across North America and the European Union.
SILA vs SLNO — Head-to-Head
Income Statement — Q4 FY2025 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $50.1M | $66.0M |
| Net Profit | $5.0M | $26.0M |
| Gross Margin | 88.9% | 98.3% |
| Operating Margin | — | 33.5% |
| Net Margin | 10.0% | 39.4% |
| Revenue YoY | 7.6% | — |
| Net Profit YoY | -54.9% | 134.0% |
| EPS (diluted) | $0.10 | $0.47 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $50.1M | — | ||
| Q3 25 | $49.8M | $66.0M | ||
| Q2 25 | $48.7M | $32.7M | ||
| Q1 25 | $48.3M | — | ||
| Q4 24 | $46.5M | — | ||
| Q3 24 | $46.1M | — | ||
| Q2 24 | $43.6M | — | ||
| Q1 24 | $50.6M | — |
| Q4 25 | $5.0M | — | ||
| Q3 25 | $11.6M | $26.0M | ||
| Q2 25 | $8.6M | $-4.7M | ||
| Q1 25 | $7.9M | — | ||
| Q4 24 | $11.1M | — | ||
| Q3 24 | $11.9M | — | ||
| Q2 24 | $4.6M | — | ||
| Q1 24 | $15.0M | — |
| Q4 25 | 88.9% | — | ||
| Q3 25 | 88.1% | 98.3% | ||
| Q2 25 | 87.7% | 97.9% | ||
| Q1 25 | 86.9% | — | ||
| Q4 24 | 87.3% | — | ||
| Q3 24 | 87.4% | — | ||
| Q2 24 | 86.6% | — | ||
| Q1 24 | 89.0% | — |
| Q4 25 | — | — | ||
| Q3 25 | — | 33.5% | ||
| Q2 25 | — | -20.0% | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | 10.0% | — | ||
| Q3 25 | 23.3% | 39.4% | ||
| Q2 25 | 17.6% | -14.4% | ||
| Q1 25 | 16.4% | — | ||
| Q4 24 | 23.9% | — | ||
| Q3 24 | 25.9% | — | ||
| Q2 24 | 10.6% | — | ||
| Q1 24 | 29.6% | — |
| Q4 25 | $0.10 | — | ||
| Q3 25 | $0.21 | $0.47 | ||
| Q2 25 | $0.15 | $-0.09 | ||
| Q1 25 | $0.14 | — | ||
| Q4 24 | $0.20 | — | ||
| Q3 24 | $0.21 | — | ||
| Q2 24 | $0.08 | — | ||
| Q1 24 | $0.26 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $32.3M | $498.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $1.3B | $494.8M |
| Total Assets | $2.1B | $599.9M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $32.3M | — | ||
| Q3 25 | $27.7M | $498.9M | ||
| Q2 25 | $24.8M | $286.8M | ||
| Q1 25 | $30.5M | — | ||
| Q4 24 | $39.8M | — | ||
| Q3 24 | $28.6M | — | ||
| Q2 24 | $87.0M | — | ||
| Q1 24 | $90.2M | — |
| Q4 25 | $1.3B | — | ||
| Q3 25 | $1.3B | $494.8M | ||
| Q2 25 | $1.4B | $240.1M | ||
| Q1 25 | $1.4B | — | ||
| Q4 24 | $1.4B | — | ||
| Q3 24 | $1.4B | — | ||
| Q2 24 | $1.5B | — | ||
| Q1 24 | $1.5B | — |
| Q4 25 | $2.1B | — | ||
| Q3 25 | $2.1B | $599.9M | ||
| Q2 25 | $2.0B | $332.3M | ||
| Q1 25 | $2.0B | — | ||
| Q4 24 | $2.0B | — | ||
| Q3 24 | $2.0B | — | ||
| Q2 24 | $2.1B | — | ||
| Q1 24 | $2.1B | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $119.1M | $43.5M |
| Free Cash FlowOCF − Capex | — | $43.5M |
| FCF MarginFCF / Revenue | — | 65.8% |
| Capex IntensityCapex / Revenue | — | 0.0% |
| Cash ConversionOCF / Net Profit | 23.76× | 1.67× |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $119.1M | — | ||
| Q3 25 | $30.0M | $43.5M | ||
| Q2 25 | $31.9M | $-12.6M | ||
| Q1 25 | $24.1M | — | ||
| Q4 24 | $132.8M | — | ||
| Q3 24 | $29.1M | — | ||
| Q2 24 | $31.6M | — | ||
| Q1 24 | $36.6M | — |
| Q4 25 | — | — | ||
| Q3 25 | — | $43.5M | ||
| Q2 25 | — | $-12.6M | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | — | 65.8% | ||
| Q2 25 | — | -38.6% | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | — | 0.0% | ||
| Q2 25 | — | 0.0% | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | 23.76× | — | ||
| Q3 25 | 2.59× | 1.67× | ||
| Q2 25 | 3.71× | — | ||
| Q1 25 | 3.06× | — | ||
| Q4 24 | 11.95× | — | ||
| Q3 24 | 2.43× | — | ||
| Q2 24 | 6.84× | — | ||
| Q1 24 | 2.44× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
